Probably the first order of business in regards to

New Post Public Reply Private Reply Replies (1) Message Board
bulls9999 wrestlingisking #5545

Probably the first order of business in regards to uplisting is to have SEC paperwork completed, audited financials, etc.

I think there are several requirements in regards to minimum share price, how many shares, positive revenue balance statement for X-amount of prior time (1-2 yrs?). I'll look for a link:

http://www.redchip.com/blog/index.php/uncateg...yXTo01OVaQ

SEC Approves Alternative NASDAQ Listing Requirements

A recent change in the listing requirements for the NASDAQ Capital Market gives more small-cap companies the opportunity to uplist to the senior exchange.

On April 18, the Securities and Exchange Commission approved an alternative to the $4 initial listing bid price requirement for the NasdaqCM. The rule change is meant to level the playing field between the NASDAQ Stock Market and its main competitor, the NYSE Amex. Prior to the rule change, the NYSE Amex required companies to have a minimum stock price of $2 to $3, while the NasdaqCM required a price of $4. As a result, numerous small-cap stocks trading between $2 and $4 were shut out of the NasdaqCM. According to the NASDAQ Stock Market’s proposal, filed in January, “A number of companies have indicated a preference to initially list on the Capital Market instead of NYSE Amex and have expressed frustration at their inability to do so without reverse splitting their stock.”

Under the new NasdaqCM requirements, a stock can qualify for listing if it closes at $3 or above for at least five consecutive business days prior to approval. The five-day requirement is in place to reduce the risk of price manipulation aimed at allowing a security to qualify for listing. In addition to the $3 share price requirement, the company must meet the following requirements:

  • Stockholders’ equity of at least $5 million
  • Market value of publicly held shares of at least $15 million
  • Two years of operating history

Or:

  • Net income from continuing operations of $750,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years
  • Stockholders’ equity of at least $4 million
  • Market value of publicly held shares of at least $5 million.

Securities with a $2 minimum closing price for five consecutive business days prior to the approval can also qualify for listing on the NasdaqCM if they meet the Market Value of Listed Securities Standard, which requires a market value of listed securities of at least $50 million, stockholders’ equity of at least $4 million, and a market value of publicly held shares of at least $15 million

In addition, companies must demonstrate that they have more than $2 million in net tangible assets if they have been in continuous operation for at least three years, or more than $5 million if they’ve been in continuous operation for less than three years. A company must also have average revenue of at least $6 million for the past three years. All other requirements for listing on the Capital Market are the same or higher than those of the NYSE Amex. A copy of the NASDAQ Stock Market’s original proposal is available on the SEC website.

With the new requirements, the NASDAQ Stock Market becomes more competitive with the NYSE Amex, and emerging growth companies now have another avenue to benefit from the increased exposure, liquidity, and access to capital that comes with uplisting to a senior exchange. As would be expected, two companies that RedChip helped uplist, L & L Energy (NASDAQ: LLEN) and Longwei Petroleum (NYSE Amex: LPH) , both saw substantial valuation gains after moving to senior exchanges. Other RedChip clients that could qualify for uplisting over the next 6 to 12 months include ChromaDex Corp. (OTC BB: CDXC) , a natural products company and producer of the dietary supplement BluScience ; First Surgical Partners Inc. (OTC BB: FSPI) , a dividend-paying operator of ambulatory surgical centers; and Cross Border Resources, Inc. (OTC QX: XBOR) , an oil and gas company operating in the Permian Basin. If you are an executive or board member of an over-the-counter company and would like to learn how RedChip can help your company, contact us today.

Disclosure: The subject securities are clients of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv .

Creative Edge Nutrition Inc. (FITX) Stock Research Links

FITX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

TSA PreCheck Study Reveals Time Savings and Travel Insights

Updated Category News Views 379

Understanding TSA PreCheck's Impact on Travelers The latest survey reveals some interesting insights about TSA PreCheck, especially concerning the time savings that members experience at security checkpoints. Conducted by Upgraded Points, this enlightening study assessed the experience of over 1,500 travelers to evaluate the true advantages of holding a TSA PreCheck...

Continue Reading
Intermap Technologies Enhances Geospatial Solutions with New Offering

Updated Category News Views 217

Intermap Technologies Announces New Prospectus Supplement DENVER – Intermap Technologies Corporation (TSX: IMP; OTCQB: ITMSF), a recognized leader in 3D geospatial products and intelligence solutions, has filed a prospectus supplement in the context of a strategically planned public offering. This initiative signifies a promising step forward, with the company aiming to...

Continue Reading
Urgent Investor Notice: Humacyte Legal Claims Investigation

Updated Category News Views 94

Critical Deadline for Humacyte Investors Approaches As time runs short, investors in Humacyte, Inc. (NASDAQ: HUMA) should pay attention. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating claims on behalf of investors who have suffered losses exceeding $75,000 due to potential violations in federal securities laws. Understanding Your...

Continue Reading
Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab

Updated Category News Views 226

Empowering Women in Banking: Natalie Bartholomew at Alkami Co:lab Natalie Bartholomew, a highly recognized advocate for women in financial services, will be the featured speaker for the Women in Banking session at Alkami Co:lab 2026. Her expertise and passion are expected to inspire attendees and foster discussions around women's roles in the financial sector. Alkami...

Continue Reading
Investors Anticipate Strong Earnings from OPAL Fuels Soon

Updated Category News Views 161

OPAL Fuels Earnings Report Insights OPAL Fuels OPAL is preparing to release its quarterly earnings report soon, and investors are keenly interested in the results. As the anticipated date for this report approaches, it is essential for investors to stay informed and understand what the expectations are. Projected Earnings Overview Analysts project that OPAL Fuels will...

Continue Reading